Recent executive actions have accelerated federal cannabis policy shifts. President Trump's December 2025 order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. In April 2026, the Department of Justice and DEA issued a final order immediately rescheduling FDA-approved products and state-licensed medical marijuana to Schedule III, effective April 28. This partial change provides immediate regulatory relief for medical operators while preserving controls on illicit trafficking. An expedited DEA administrative hearing, set to begin June 29, 2026, will evaluate broader rescheduling for all marijuana forms through formal rulemaking. These verified developments, building on 2024 HHS recommendations, represent the dominant recent catalysts shaping trader assessments of timelines and scope.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$765,952 Vol.
30. Juni
2%
31. Dezember
27%
$765,952 Vol.
30. Juni
2%
31. Dezember
27%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent executive actions have accelerated federal cannabis policy shifts. President Trump's December 2025 order directed expedited rulemaking to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. In April 2026, the Department of Justice and DEA issued a final order immediately rescheduling FDA-approved products and state-licensed medical marijuana to Schedule III, effective April 28. This partial change provides immediate regulatory relief for medical operators while preserving controls on illicit trafficking. An expedited DEA administrative hearing, set to begin June 29, 2026, will evaluate broader rescheduling for all marijuana forms through formal rulemaking. These verified developments, building on 2024 HHS recommendations, represent the dominant recent catalysts shaping trader assessments of timelines and scope.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen